Key result
COVID-19 is linked to altered hypercoagulability markers including D-dimer, PT, and troponin in ACS.
Why the study?
COVID-19 causes systemic inflammation and pulmonary complications, but cardiovascular issues can also occur, prompting research aimed at reducing the risk of myocardial infarction in these patients.
Does COVID-19 infection increase the risk of acute coronary syndrome through hypercoagulability?
Case-Control (n=129)
No
Does COVID-19 infection increase the risk of acute coronary syndrome through hypercoagulability?
Hypercoagulability associated with COVID-19 infection may increase the likelihood of acute coronary syndrome.
May support heightened MI vigilance in COVID-19; leaves open causal links pending randomized data.
Background: The coronavirus illness of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (COVID-2) (SARS-CoV-2). Although systemic inflammation and lung complications can result in significant morbidity and mortality, cardiovascular issues can also occur. Aim of The Work: Reducing risk of myocardial infarction in patients with COVID-19. Subjects and methods: This Case-control study was conducted in Shark El-Madina hospital in Alexandria on 129 covid-19 patients divided into group A: 43 suspected COVID-19 patients who developed Acute coronary syndrome (ACS), group B: 43 suspected COVID-19 patients who hasn`t developed ACS and group C: 43 patients with myocardial infarction who were not suspected for COVID-19. All patients underwent thorough general and local history taking, a physical exam, routine tests (CBC, CRP, ESR and blood gases) and CT chest as well as specialised tests like the ECG, ferritin, PT, PTT, INR, D. dimer, Troponin, and LDH. Results: There was differences between the three groups in terms of Troponin level, D-dimer, Ferritin, CRP, ALT, AST and PT Conclusion: Based on our study findings, we concluded that hypercoagulability of Acute coronary syndrome is more likely to manifest in people with Covid 19 infection.
No takes yet. Share an insight, caveat, or question.
Mahfouz et al. (2023) conducted a case-control in COVID-19 and Acute Coronary Syndrome (n=129). COVID-19 infection vs. Patients without COVID-19 or without acute coronary syndrome was evaluated on Levels of Troponin, D-dimer, Ferritin, CRP, ALT, AST and PT. COVID-19 infection was associated with differences in hypercoagulability markers including D-dimer, PT, and troponin among patients with acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: